Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

PCN Insights, News, Videos, and More

Julie Carbray, PhD
Videos
08/06/2024
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN,...
08/06/2024
Psych Congress Network
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
News
08/05/2024
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies...
08/05/2024
Psych Congress Network
nursing home care
News
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
A brain puzzle against an orange background
News
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
Doctor and patient
News
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
News
07/31/2024
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid...
07/31/2024
Psych Congress Network
Julie Carbray, PhD
Videos
07/31/2024
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she...
07/31/2024
Psych Congress Network
marc agronin md
Blog
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement